EFABP (Epidermal Fatty Acid Binding Protein, FABP5) Human (E. coli)

Description

Total 135 AA. MW: 15.2 kDa (calculated). 134 AA and one extra AA, N-terminal methionin (highlighted).

Amino Acid Sequence

Source

E. coli

Purity

>90%

SDS-PAGE gel

12% SDS-PAGE separation of Human EFABP 1. M.W. marker – 14, 21, 31, 45, 66, 97 kDa 2. reduced and heated sample, 5μg/lane 3. non-reduced and non-heated sample, 5μg/lane

Formulation

Filtered (0,4 μm) and lyophilized in 0.5 mg/mL in phosphate buffered saline

Reconstitution

Add deionized water to prepare a working stock solution of approximately 0.5 mg/mL and let the lyophilized pellet dissolve completely. Product is not sterile! Please filter the product by an appropriate sterile filter before using it in the cell culture.

Storage, Stability/Shelf Life

Store lyophilized protein at –20°C. Lyophilized protein remains stable until the expiry date when stored at –20°C. Aliquot reconstituted protein to avoid repeated freezing/thawing cycles and store at –80°C for long term storage. Reconstituted protein can be stored at 4°C for a limited period of time; it does not show any change after two weeks at 4°C.

Quality Control Test

BCA to determine quantity of the protein.

SDS PAGE to determine purity of the protein.

Applications

ELISA, Western blotting

Note

This product is intended for research use only.

Introduction to the Molecule

Human fatty acid binding protein EFABP is a 15 kD member of the intracellular fatty acid binding protein (FABP) family, which is known for the ability to bind fatty acids and related compounds ( bile acids or retinoids). in an internal cavity. The fatty acid binding proteins aP2 (fatty acid binding protein [FABP]-4) and mal1 (EFABP) are closely related and both are expressed in adipocytes. Absence of EFABP/mal1 resulted in increased systemic insulin sensitivity in two models of obesity and insulin resistance. Adipocytes isolated from mal1-deficient mice also exhibited enhanced insulin-stimulated glucose transport capacity. In contrast, mice expressing high levels of mal1 in adipose tissue display reduced systemic insulin sensitivity .

References to this Product

• Stejskal D, Karpisek M . Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome?. Eur J Clin Invest . Sep;36(9):621-5 (2006)
• Haider DG, Schindler K, Bohdjalian A, Prager G, Luger A, Wolzt M, Ludvik B . Plasma adipocyte and epidermal fatty acid binding protein is reduced after weight loss in obesity. Diabetes Obes Metab . Mar 13 (2007)
• Housova J, Anderlova K, Krizova J, Haluzikova D, Kremen J, Kumstyrova T, Papezova H, Haluzik M . Serum adiponectin and resistin concentrations in patients with restrictive and binge/purge form of anorexia nervosa and buliminia nervosa. J Clin Endocrinol Metab . Dec 14 (2004) [Epub ahead of print]

References

• Fisher RM, Hoffstedt J, Hotamisligil GS, Thorne A, Ryden M. Effects of obesity and weight loss on the expression of proteins involved in fatty acid metabolism in human adipose tissue.
• Jenkins-Kruchten AE, Bennaars-Eiden A, Ross JR, Shen WJ, Kraemer FB, Bernlohr DA. Fatty acid-binding protein-hormone-sensitive lipase interaction.
• Maeda K, Uysal KT, Makowski L, Gorgun CZ, Atsumi G, Parker RA, Bruning J, Hertzel AV, Bernlohr DA, Hotamisligil GS. Role of the fatty acid binding protein mal1 in obesity and insulin resistance.